Beyond hepatic stellate cell heterogeneity: Resolving fibrosis, restoring regeneration (Review)

Campana L, Esser H, Huch M and Forbes S: Liver regeneration and inflammation: From fundamental science to clinical applications. Nat Rev Mol Cell Biol. 22:608–624. 2021. View Article : Google Scholar : PubMed/NCBI

Wake K: 'Sternzellen' in the liver. Perisinusoidal cells with special reference to storage of vitamin A. Am J Anat. 132:429–462. 1971. View Article : Google Scholar : PubMed/NCBI

Cogliati B, Yashaswini CN, Wang S, Sia D and Friedman SL: Friend or foe? The elusive role of hepatic stellate cells in liver cancer. Nat Rev Gastroenterol Hepatol. 20:647–661. 2023. View Article : Google Scholar : PubMed/NCBI

Kamm DR and McCommis KS: Hepatic stellate cells in physiology and pathology. J Physiol. 600:1825–1837. 2022. View Article : Google Scholar : PubMed/NCBI

Chen L, Ye X, Yang L, Zhao J, You J and Feng Y: Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells. J Natl Cancer Cent. 4:25–35. 2024.PubMed/NCBI

Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI

Yang T, Gu Z, Feng J, Shan J, Qian C and Zhuang N: Non-parenchymal cells: Key targets for modulating chronic liver disease. Front Immunol. 16:15767392025. View Article : Google Scholar

Shu W, Yang M, Yang J, Lin S, Wei X and Xu X: Cellular crosstalk during liver regeneration: unity in diversity. Cell Commun Signal. 20:1172022. View Article : Google Scholar : PubMed/NCBI

Trefts E, Gannon M and Wasserman DH: The liver. Curr Biol. 27:R1147–R1151. 2017. View Article : Google Scholar : PubMed/NCBI

Carter JK and Friedman SL: Hepatic stellate cell-immune interactions in NASH. Front Endocrinol (Lausanne). 13:8679402022. View Article : Google Scholar : PubMed/NCBI

Xia M, Li J, Martinez Aguilar LM, Wang J, Trillos Almanza MC, Li Y, Buist-Homan M and Moshage H: Arctigenin attenuates hepatic stellate cell activation via endoplasmic reticulum-associated degradation (ERAD)-Mediated restoration of lipid homeostasis. J Agric Food Chem. 73:13918–13933. 2025. View Article : Google Scholar : PubMed/NCBI

Kisseleva T: The origin of fibrogenic myofibroblasts in fibrotic liver. Hepatology. 65:1039–1043. 2017. View Article : Google Scholar

Wiering L, Subramanian P and Hammerich L: Hepatic stellate cells: Dictating outcome in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 15:1277–1292. 2023. View Article : Google Scholar : PubMed/NCBI

Acharya P, Chouhan K, Weiskirchen S and Weiskirchen R: Cellular mechanisms of liver fibrosis. Front Pharmacol. 12:6716402021. View Article : Google Scholar : PubMed/NCBI

Nishio T, Hu R, Koyama Y, Liang S, Rosenthal SB, Yamamoto G, Karin D, Baglieri J, Ma HY, Xu J, et al: Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol. 71:573–585. 2019. View Article : Google Scholar : PubMed/NCBI

Kim HY, Sakane S, Eguileor A, Carvalho Gontijo Weber R, Lee W, Liu X, Lam K, Ishizuka K, Rosenthal SB, Diggle K, et al: The origin and fate of liver myofibroblasts. Cell Mol Gastroenterol Hepatol. 17:93–106. 2024. View Article : Google Scholar

Yang W, He H, Wang T, Su N, Zhang F, Jiang K, Zhu J, Zhang C, Niu K, Wang L, et al: Single-Cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology. 74:2774–2790. 2021. View Article : Google Scholar : PubMed/NCBI

Hernandez-Gea V and Friedman SL: Pathogenesis of liver fibrosis. Annu Rev Pathol. 6:425–456. 2011. View Article : Google Scholar

Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R and Tacke F: Single Cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblasts in liver fibrosis. Cells. 8:5032019. View Article : Google Scholar : PubMed/NCBI

Tsuchida T and Friedman SL: Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 14:397–411. 2017. View Article : Google Scholar : PubMed/NCBI

Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, et al: Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature. 575:512–518. 2019. View Article : Google Scholar : PubMed/NCBI

Cheng S, Zou Y, Zhang M, Bai S, Tao K, Wu J, Shi Y, Wu Y, Lu Y, He K, et al: Single-cell RNA sequencing reveals the heterogeneity and intercellular communication of hepatic stellate cells and macrophages during liver fibrosis. MedComm (2020). 4:e3782023. View Article : Google Scholar : PubMed/NCBI

Deng G, Liang X, Pan Y, Luo Y, Luo Z, He S, Huang S, Chen Z, Wang J and Fang S: Single-cell transcriptomic analysis of different liver fibrosis models: Elucidating molecular distinctions and commonalities. Biomedicines. 13:17882025. View Article : Google Scholar : PubMed/NCBI

Wang ZY, Keogh A, Waldt A, Cuttat R, Neri M, Zhu S, Schuierer S, Ruchti A, Crochemore C, Knehr J, et al: Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci Rep. 11:193962021. View Article : Google Scholar : PubMed/NCBI

Peyser R, MacDonnell S, Gao Y, Cheng L, Kim Y, Kaplan T, Ruan Q, Wei Y, Ni M, Adler C, et al: Defining the activated fibroblast population in lung fibrosis using single-cell sequencing. Am J Respir Cell Mol Biol. 61:74–85. 2019. View Article : Google Scholar : PubMed/NCBI

Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, Lee KH, Geng Y, Rajbhandari P, Hernandez C, Steffani M, et al: Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature. 640:752–761. 2025. View Article : Google Scholar : PubMed/NCBI

Geng Y and Schwabe RF: Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications. Hepatology. May 8–2025.Epub ahead of print. View Article : Google Scholar

Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP and Schwabe RF: Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 4:28232013. View Article : Google Scholar : PubMed/NCBI

Wang SS, Tang XT, Lin M, Yuan J, Peng YJ, Yin X, Shang G, Ge G, Ren Z and Zhou BO: Perivenous stellate cells are the main source of myofibroblasts and cancer-associated fibroblasts formed after chronic liver injuries. Hepatology. 74:1578–1594. 2021. View Article : Google Scholar : PubMed/NCBI

Rosenthal SB, Liu X, Ganguly S, Dhar D, Pasillas MP, Ricciardelli E, Li RZ, Troutman TD, Kisseleva T, Glass CK and Brenner DA: Heterogeneity of HSCs in a mouse model of NASH. Hepatology. 74:667–685. 2021. View Article : Google Scholar : PubMed/NCBI

MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, Manuel J, Khuu N, Echeverri J, Linares I, et al: Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. 9:43832018. View Article : Google Scholar : PubMed/NCBI

Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, et al: Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 75:644–660.e5. 2019. View Article : Google Scholar : PubMed/NCBI

Lotto J, Drissler S, Cullum R, Wei W, Setty M, Bell EM, Boutet SC, Nowotschin S, Kuo YY, Garg V, et al: Single-cell transcriptomics reveals early emergence of liver parenchymal and non-parenchymal cell lineages. Cell. 183:702–716 e14. 2020. View Article : Google Scholar : PubMed/NCBI

Liu X, Xu J, Rosenthal S, Zhang LJ, McCubbin R, Meshgin N, Shang L, Koyama Y, Ma HY, Sharma S, et al: Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology. 158:1728–1744.e14. 2020. View Article : Google Scholar : PubMed/NCBI

Su Q, Kim SY, Adewale F, Zhou Y, Aldler C, Ni M, Wei Y, Burczynski ME, Atwal GS, Sleeman MW, et al: Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver. iScience. 24:1032332021. View Article : Google Scholar : PubMed/NCBI

Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, Fu Y, Li N, He Y, Liu C, et al: ECM1 prevents activation of transforming growth factor β, hepatic stellate cells, and fibrogenesis in mice. Gastroenterology. 157:1352–1367.e13. 2019. View Article : Google Scholar

Ben-Moshe S and Itzkovitz S: Spatial heterogeneity in the mammalian liver. Nat Rev Gastroenterol Hepatol. 16:395–410. 2019. View Article : Google Scholar : PubMed/NCBI

Dobie R, Wilson-Kanamori JR, Henderson BEP, Smith JR, Matchett KP, Portman JR, Wallenborg K, Picelli S, Zagorska A, Pendem SV, et al: Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep. 29:1832–1847.e8. 2019. View Article : Google Scholar : PubMed/NCBI

Watson BR, Paul B, Rahman RU, Amir-Zilberstein L, Segerstolpe Å, Epstein ET, Murphy S, Geistlinger L, Lee T, Shih A, et al: Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution. Nat Commun. 16:3192025. View Article : Google Scholar : PubMed/NCBI

Khan MA, Fischer J, Harrer L, Schwiering F, Groneberg D and Friebe A: Hepatic stellate cells in zone 1 engage in capillarization rather than myofibroblast formation in murine liver fibrosis. Sci Rep. 14:188402024. View Article : Google Scholar : PubMed/NCBI

Ramm GA, Britton RS, O'Neill R, Blaner WS and Bacon BR: Vitamin A-poor lipocytes: A novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts. Am J Physiol. 269(4 Pt 1): G532–G541. 1995.PubMed/NCBI

Ballardini G, Groff P, Badiali de Giorgi L, Schuppan D and Bianchi FB: Ito cell heterogeneity: Desmin-negative Ito cells in normal rat liver. Hepatology. 19:440–446. 1994. View Article : Google Scholar : PubMed/NCBI

D'Ambrosio DN, Walewski JL, Clugston RD, Berk PD, Rippe RA and Blaner WS: Distinct populations of hepatic stellate cells in the mouse liver have different capacities for retinoid and lipid storage. PLoS One. 6:e249932011. View Article : Google Scholar : PubMed/NCBI

Payen VL, Lavergne A, Alevra Sarika N, Colonval M, Karim L, Deckers M, Najimi M, Coppieters W, Charloteaux B, Sokal EM and El Taghdouini A: Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity. JHEP Rep. 3:1002782021. View Article : Google Scholar : PubMed/NCBI

Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, et al: Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci USA. 109:9448–9453. 2012. View Article : Google Scholar : PubMed/NCBI

Guo Q, Wu J, Wang Q, Huang Y, Chen L, Gong J, Du M, Cheng G, Lu T, Zhao M, et al: Single-cell transcriptome analysis uncovers underlying mechanisms of acute liver injury induced by tripterygium glycosides tablet in mice. J Pharm Anal. 13:908–925. 2023. View Article : Google Scholar : PubMed/NCBI

Cook D, Achanta S, Hoek JB, Ogunnaike BA and Vadigepalli R: Cellular network modeling and single cell gene expression analysis reveals novel hepatic stellate cell phenotypes controlling liver regeneration dynamics. BMC Syst Biol. 12:862018. View Article : Google Scholar : PubMed/NCBI

Kolodziejczyk AA, Federici S, Zmora N, Mohapatra G, Dori-Bachash M, Hornstein S, Leshem A, Reuveni D, Zigmond E, Tobar A, et al: Acute liver failure is regulated by MYC- and microbiome-dependent programs. Nat Med. 26:1899–1911. 2020. View Article : Google Scholar : PubMed/NCBI

Kostallari E, Wei B, Sicard D, Li J, Cooper SA, Gao J, Dehankar M, Li Y, Cao S, Yin M, et al: Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 322:G234–G246. 2022. View Article : Google Scholar :

Andrews TS, Atif J, Liu JC, Perciani CT, Ma XZ, Thoeni C, Slyper M, Eraslan G, Segerstolpe A, Manuel J, et al: Single-cell, single-nucleus, and spatial RNA sequencing of the human liver identifies cholangiocyte and mesenchymal heterogeneity. Hepatol Commun. 6:821–840. 2022. View Article : Google Scholar

Wang S, Li K, Pickholz E, Dobie R, Matchett KP, Henderson NC, Carrico C, Driver I, Borch Jensen M, Chen L, et al: An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis. Sci Transl Med. 15:d39492023. View Article : Google Scholar

He W, Huang C, Shi X, Wu M, Li H, Liu Q, Zhang X, Zhao Y and Li X: Single-cell transcriptomics of hepatic stellate cells uncover crucial pathways and key regulators involved in non-alcoholic steatohepatitis. Endocr Connect. 12:e2205022023. View Article : Google Scholar :

Cavalli M, Diamanti K, Pan G, Spalinskas R, Kumar C, Deshmukh AS, Mann M, Sahlén P, Komorowski J and Wadelius C: A multi-omics approach to liver diseases: Integration of single nuclei transcriptomics with proteomics and HiCap bulk data in human liver. OMICS. 24:180–194. 2020. View Article : Google Scholar : PubMed/NCBI

Terkelsen MK, Bendixen SM, Hansen D, Scott EAH, Moeller AF, Nielsen R, Mandrup S, Schlosser A, Andersen TL, Sorensen GL, et al: Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury. Hepatology. 72:2119–2133. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang W, Conway SJ, Liu Y, Snider P, Chen H, Gao H, Liu Y, Isidan K, Lopez KJ, Campana G, et al: Heterogeneity of hepatic stellate cells in fibrogenesis of the liver: Insights from single-cell transcriptomic analysis in liver injury. Cells. 10:21292021. View Article : Google Scholar : PubMed/NCBI

Yin L, Qi Y, Xu Y, Xu L, Han X, Tao X, Song S and Peng J: Dioscin Inhibits HSC-T6 cell migration via adjusting SDC-4 Expression: Insights from iTRAQ-Based quantitative proteomics. Front Pharmacol. 8:6652017. View Article : Google Scholar : PubMed/NCBI

Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, Liepelt A, Lefebvre E, Luedde T, Hellerbrand C, et al: Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 67:1270–1283. 2018. View Article : Google Scholar

Nevi L, Costantini D, Safarikia S, Di Matteo S, Melandro F, Berloco PB and Cardinale V: Cholest-4,6-Dien-3-One promote epithelial-to-mesenchymal transition (EMT) in biliary tree stem/progenitor cell cultures in vitro. Cells. 8:14432019. View Article : Google Scholar : PubMed/NCBI

Wang Y, Nakajima T, Gonzalez FJ and Tanaka N: PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-Null mice. Int J Mol Sci. 21:20612020. View Article : Google Scholar : PubMed/NCBI

Katsumata LW, Miyajima A and Itoh T: Portal fibroblasts marked by the surface antigen Thy1 contribute to fibrosis in mouse models of cholestatic liver injury. Hepatol Commun. 1:198–214. 2017. View Article : Google Scholar

Balog S, Fujiwara R, Pan SQ, El-Baradie KB, Choi HY, Sinha S, Yang Q, Asahina K, Chen Y, Li M, et al: Emergence of highly profibrotic and proinflammatory Lrat+Fbln2+ HSC subpopulation in alcoholic hepatitis. Hepatology. 78:212–224. 2023. View Article : Google Scholar

Li X, Wang Q, Ai L and Cheng K: Unraveling the activation process and core driver genes of HSCs during cirrhosis by single-cell transcriptome. Exp Biol Med (Maywood). 248:1414–1424. 2023. View Article : Google Scholar : PubMed/NCBI

Chung BK, Ogaard J, Reims HM, Karlsen TH and Melum E: Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis. Hepatol Commun. 6:2538–2550. 2022. View Article : Google Scholar : PubMed/NCBI

Fred RG, Steen PJ, Thompson JJ, Lee J, Timshel PN, Stender S, Opseth Rygg M, Gluud LL, Bjerregaard Kristiansen V, Bendtsen F, et al: Single-cell transcriptome and cell type-specific molecular pathways of human non-alcoholic steatohepatitis. Sci Rep. 12:134842022. View Article : Google Scholar : PubMed/NCBI

Wang Z, Zhao Z, Xia Y, Cai Z, Wang C, Shen Y, Liu R, Qin H, Jia J and Yuan G: Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH). J Endocrinol Invest. 45:1379–1392. 2022. View Article : Google Scholar : PubMed/NCBI

Filliol A, Saito Y, Nair A, Dapito DH, Yu LX, Ravichandra A, Bhattacharjee S, Affo S, Fujiwara N, Su H, et al: Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature. 610:356–365. 2022. View Article : Google Scholar : PubMed/NCBI

Yu Y, Li Y, Zhou L, Cheng X and Gong Z: Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses. Cancer Lett. 604:2172432024. View Article : Google Scholar : PubMed/NCBI

Wu J, Sun X, Wu C, Hong X, Xie L, Shi Z, Zhao L, Du Q, Xiao W, Sun J and Wang J: Single-cell transcriptome analysis reveals liver injury induced by glyphosate in mice. Cell Mol Biol Lett. 28:112023. View Article : Google Scholar : PubMed/NCBI

Bai YM, Yang F, Luo P, Xie LL, Chen JH, Guan YD, Zhou HC, Xu TF, Hao HW, Chen B, et al: Single-cell transcriptomic dissection of the cellular and molecular events underlying the triclosan-induced liver fibrosis in mice. Mil Med Res. 10:72023.PubMed/NCBI

Hu S, Tang B, Lu C, Wang S, Wu L, Lei Y, Tang L, Zhu H, Wang D and Yang S: Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis. Pharmacol Res. 206:1072752024. View Article : Google Scholar : PubMed/NCBI

Yang AT, Kim YO, Yan XZ, Abe H, Aslam M, Park KS, Zhao XY, Jia JD, Klein T, You H and Schuppan D: Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell Mol Gastroenterol Hepatol. 15:841–867. 2023. View Article : Google Scholar :

Li Y, Sheng Q, Zhang C, Han C, Bai H, Lai P, Fan Y, Ding Y and Dou X: STAT6 up-regulation amplifies M2 macrophage anti-inflammatory capacity through mesenchymal stem cells. Int Immunopharmacol. 91:1072662021. View Article : Google Scholar

Kimura Y, Koyama Y, Taura K, Kudoh A, Echizen K, Nakamura D, Li X, Nam NH, Uemoto Y, Nishio T, et al: Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice. Hepatology. 77:443–455. 2023. View Article : Google Scholar

Kumar S, Duan Q, Wu R, Harris EN and Su Q: Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev. 176:1138692021. View Article : Google Scholar : PubMed/NCBI

Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L and Lowe SW: Senescence of activated stellate cells limits liver fibrosis. Cell. 134:657–667. 2008. View Article : Google Scholar : PubMed/NCBI

Bernard M, Yang B, Migneault F, Turgeon J, Dieudé M, Olivier MA, Cardin GB, El-Diwany M, Underwood K, Rodier F and Hébert MJ: Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy. 16:2004–2016. 2020. View Article : Google Scholar : PubMed/NCBI

Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, et al: Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 499:97–101. 2013. View Article : Google Scholar : PubMed/NCBI

Yashaswini CN, Qin T, Bhattacharya D, Amor C, Lowe S, Lujambio A, Wang S and Friedman SL: Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J Hepatol. 81:207–217. 2024. View Article : Google Scholar : PubMed/NCBI

Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E and Kamath PS: Global burden of liver disease: 2023 update. J Hepatol. 79:516–537. 2023. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Zhang L, Ma Y, Xie L, Yang YY, Jin C, Chen H, Zhou Y, Song GQ, Ding J and Wu J: Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma. Theranostics. 13:4430–4448. 2023. View Article : Google Scholar : PubMed/NCBI

Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V and Lowe SW: Non-cell-autonomous tumor suppression by p53. Cell. 153:449–460. 2013. View Article : Google Scholar : PubMed/NCBI

Cheng N, Kim KH and Lau LF: Senescent hepatic stellate cells promote liver regeneration through IL-6 and ligands of CXCR2. JCI Insight. 7:e1582072022. View Article : Google Scholar : PubMed/NCBI

Ramachandran P, Matchett KP, Dobie R, Wilson-Kanamori JR and Henderson NC: Single-cell technologies in hepatology: New insights into liver biology and disease pathogenesis. Nat Rev Gastroenterol Hepatol. 17:457–472. 2020. View Article : Google Scholar : PubMed/NCBI

Xu J, Ma H, Liang S, Sun M, Karin G, Koyama Y, Hu R, Quehenberger O, Davidson NO, Dennis EA, et al: The role of human cytochrome P450 2E1 in liver inflammation and fibrosis. Hepatol Commun. 1:1043–1057. 2017. View Article : Google Scholar

Ben-Moshe S, Veg T, Manco R, Dan S, Papinutti D, Lifshitz A, Kolodziejczyk AA, Bahar Halpern K, Elinav E and Itzkovitz S: The spatiotemporal program of zonal liver regeneration following acute injury. Cell Stem Cell. 29:973–989.e10. 2022. View Article : Google Scholar : PubMed/NCBI

Jain I, Brougham-Cook A and Underhill GH: Effect of distinct ECM microenvironments on the genome-wide chromatin accessibility and gene expression responses of hepatic stellate cells. Acta Biomater. 167:278–292. 2023. View Article : Google Scholar : PubMed/NCBI

Brougham-Cook A, Jain I, Kukla DA, Masood F, Kimmel H, Ryoo H, Khetani SR and Underhill GH: High throughput interrogation of human liver stellate cells reveals microenvironmental regulation of phenotype. Acta Biomater. 138:240–253. 2022. View Article : Google Scholar :

Cai X, Wang J, Wang J, Zhou Q, Yang B, He Q and Weng Q: Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy. Pharmacol Res. 155:1047202020. View Article : Google Scholar : PubMed/NCBI

Li W, Chang N and Li L: Heterogeneity and function of kupffer cells in liver injury. Front Immunol. 13:9408672022. View Article : Google Scholar : PubMed/NCBI

Dai Q, Ain Q, Seth N, Rooney M and Zipprich A: Liver sinusoidal endothelial cells: Friend or foe in metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. Dig Liver Dis. 57:493–503. 2025. View Article : Google Scholar : PubMed/NCBI

Wang Z, Du K, Jin N, Tang B and Zhang W: Macrophage in liver fibrosis: Identities and mechanisms. Int Immunopharmacol. 120:1103572023. View Article : Google Scholar : PubMed/NCBI

Walesky CM, Kolb KE, Winston CL, Henderson J, Kruft B, Fleming I, Ko S, Monga SP, Mueller F, Apte U, et al: Functional compensation precedes recovery of tissue mass following acute liver injury. Nat Commun. 11:57852020. View Article : Google Scholar : PubMed/NCBI

Lee YA, Wallace MC and Friedman SL: Pathobiology of liver fibrosis: A translational success story. Gut 2015. 64:830–841. 2015.

Wang L, Feng J, Deng Y, Yang Q, Wei Q, Ye D, Rong X and Guo J: CCAAT/enhancer-binding proteins in fibrosis: Complex roles beyond conventional understanding. Research (Wash DC). 2022:98916892022.

Lee W, Liu X, Rosenthal SB, Miciano C, Sakane S, Hokutan K, Dhar D, Kim HY, Brenner DA and Kisseleva T: ETS1 suppresses hepatic stellate cell activation and liver fibrosis. JCI Insight. Nov 4–2025.Epub ahead of print. View Article : Google Scholar

Altamirano-Barrera A, Barranco-Fragoso B and Mendez-Sanchez N: Management strategies for liver fibrosis. Ann Hepatol. 16:48–56. 2017. View Article : Google Scholar : PubMed/NCBI

Guan Y, Fang Z, Hu A, Roberts S, Wang M, Ren W, Johansson PK, Heilshorn SC, Enejder A and Peltz G: Live-cell imaging of human liver fibrosis using hepatic micro-organoids. JCI Insight. 10:e1870992024. View Article : Google Scholar : PubMed/NCBI

Duspara K, Bojanic K, Pejic JI, Kuna L, Kolaric TO, Nincevic V, Smolic R, Vcev A, Glasnovic M, Curcic IB and Smolic M: Targeting the Wnt signaling pathway in liver fibrosis for drug options: An update. J Clin Transl Hepatol. 9:960–971. 2021.PubMed/NCBI

Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K and Tsukamoto H: Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 294:G39–G49. 2008. View Article : Google Scholar

Lv X, Liu C, Liu S, Li Y, Wang W, Li K, Hua F, Cui B, Zhang X, Yu J, et al: The cell cycle inhibitor P21 promotes the development of pulmonary fibrosis by suppressing lung alveolar regeneration. Acta Pharm Sin B. 12:735–746. 2022. View Article : Google Scholar : PubMed/NCBI

Xu R, Zhang L, Pan H and Zhang Y: Retinoid X receptor heterodimers in hepatic function: Structural insights and therapeutic potential. Front Pharmacol. 15:14646552024. View Article : Google Scholar : PubMed/NCBI

Friedman SL and Weiskirchen R: Working with immortalized hepatic stellate cell lines. Methods Mol Biol. 2669:129–162. 2023. View Article : Google Scholar : PubMed/NCBI

Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS and Gao B: Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 56:1150–1159. 2012. View Article : Google Scholar : PubMed/NCBI

Wang TW, Johmura Y, Suzuki N, Omori S, Migita T, Yamaguchi K, Hatakeyama S, Yamazaki S, Shimizu E, Imoto S, et al: Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature. 611:358–364. 2022. View Article : Google Scholar : PubMed/NCBI

Akkiz H, Gieseler RK and Canbay A: Liver fibrosis: From basic science towards clinical progress, focusing on the central role of hepatic stellate cells. Int J Mol Sci. 25:78732024. View Article : Google Scholar : PubMed/NCBI

Du K, Maeso-Diaz R, Oh SH, Wang E, Chen T, Pan C, Xiang K, Dutta RK, Wang XF, Chi JT and Diehl AM: Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 77:1998–2015. 2023. View Article : Google Scholar : PubMed/NCBI

Liu R, Li Y, Zheng Q, Ding M, Zhou H and Li X: Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead. Acta Pharm Sin B. 14:1009–1029. 2024. View Article : Google Scholar : PubMed/NCBI

Page A, Paoli P, Moran Salvador E, White S, French J and Mann J: Hepatic stellate cell transdifferentiation involves genome-wide remodeling of the DNA methylation landscape. J Hepatol. 64:661–673. 2016. View Article : Google Scholar :

Li N, Liu S, Zhang Y, Yu L, Hu Y, Wu T, Fang M and Xu Y: Transcriptional activation of matricellular protein spondin2 (SPON2) by BRG1 in vascular endothelial cells promotes macrophage chemotaxis. Front Cell Dev Biol. 8:7942020. View Article : Google Scholar : PubMed/NCBI

Gotze S, Schumacher EC, Kordes C and Häussinger D: Epigenetic changes during Hepatic stellate cell activation. PLoS One. 10:e1287452015. View Article : Google Scholar

Dewidar B, Meyer C, Dooley S and Meindl-Beinker AN: TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells. 8:14192019. View Article : Google Scholar

Huang YH, Yang YL and Wang FS: The role of miR-29a in the regulation, function, and signaling of liver fibrosis. Int J Mol Sci. 19:18892018. View Article : Google Scholar : PubMed/NCBI

Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deursen J, Sicard D, et al: P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts. Gastroenterology. 154:2209–2221.e14. 2018. View Article : Google Scholar : PubMed/NCBI

Paluvai H, Di Giorgio E and Brancolini C: The histone code of senescence. Cells. 9:4662020. View Article : Google Scholar : PubMed/NCBI

Dong F, Jiang S, Li J, Wang Y, Zhu L, Huang Y, Jiang X, Hu X, Zhou Q, Zhang Z and Bao Z: The histone demethylase KDM4D promotes hepatic fibrogenesis by modulating Toll-like receptor 4 signaling pathway. EBioMedicine. 39:472–483. 2019. View Article : Google Scholar :

Gerovska D, Garcia-Gallastegi P, Crende O, Márquez J, Larrinaga G, Unzurrunzaga M, Araúzo-Bravo MJ and Badiola I: GeromiRs are downregulated in the tumor microenvironment during colon cancer colonization of the liver in a murine metastasis model. Int J Mol Sci. 22:48192021. View Article : Google Scholar : PubMed/NCBI

Gholizadeh M, Szelag-Pieniek S, Post M, Kurzawski M, Prieto J, Argemi J, Drozdzik M and Kaderali L: Identifying differentially expressed MicroRNAs, target genes, and key pathways deregulated in patients with liver diseases. Int J Mol Sci. 21:73682020. View Article : Google Scholar : PubMed/NCBI

Chen X, Li WX, Chen Y, Li XF, Li HD, Huang HM, Bu FT, Pan XY, Yang Y, Huang C, et al: Suppression of SUN2 by DNA methylation is associated with HSCs activation and hepatic fibrosis. Cell Death Dis. 9:10212018. View Article : Google Scholar : PubMed/NCBI

Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, et al: Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 73:896–905. 2020. View Article : Google Scholar : PubMed/NCBI

Horn P and Tacke F: Metabolic reprogramming in liver fibrosis. Cell Metab. 36:1439–1455. 2024. View Article : Google Scholar : PubMed/NCBI

McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR and Finck BN: Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 65:1543–1556. 2017. View Article : Google Scholar

Benedicto AM, Lucantoni F, Fuster-Martinez I, Diaz-Pozo P, Dorcaratto D, Muñoz-Forner E, Victor VM, Esplugues JV, Blas-García A and Apostolova N: Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation. Biomed Pharmacother. 178:1172062024. View Article : Google Scholar : PubMed/NCBI

Smith-Cortinez N, van Eunen K, Heegsma J, Serna-Salas SA, Sydor S, Bechmann LP, Moshage H, Bakker BM and Faber KN: Simultaneous induction of glycolysis and oxidative phosphorylation during activation of hepatic stellate cells reveals novel mitochondrial targets to treat liver fibrosis. Cells. 9:24562020. View Article : Google Scholar : PubMed/NCBI

Cho EH: Succinate as a regulator of hepatic stellate cells in liver fibrosis. Front Endocrinol (Lausanne). 9:4552018. View Article : Google Scholar : PubMed/NCBI

Sinha S, Aizawa S, Nakano Y, Rialdi A, Choi HY, Shrestha R, Pan SQ, Chen Y, Li M, Kapelanski-Lamoureux A, et al: Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 - β-catenin cascade to promote liver tumorigenesis. Nat Commun. 14:26512023. View Article : Google Scholar

Li J, Yao S, Zimny S, Koob D, Jin H, Wimmer R, Denk G, Tuo B and Hohenester S: The acidic microenvironment in the perisinusoidal space critically determines bile salt-induced activation of hepatic stellate cells. Commun Biol. 7:15912024. View Article : Google Scholar : PubMed/NCBI

Yasukawa K, Shimada S, Akiyama Y, Taniai T, Igarashi Y, Tsukihara S, Tanji Y, Umemura K, Kamachi A, Nara A, et al: ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell Rep Med. 6:1020382025. View Article : Google Scholar

Kikuchi K and Tsukamoto H: Stearoyl-CoA desaturase and tumorigenesis. Chem Biol Interact. 316:1089172020. View Article : Google Scholar :

Tian XP, Wang CY, Jin XH, Li M, Wang FW, Huang WJ, Yun JP, Xu RH, Cai QQ and Xie D: Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostics. 9:1965–1979. 2019. View Article : Google Scholar : PubMed/NCBI

Gallego-Duran R, Ampuero J, Pastor-Ramirez H, Álvarez-Amor L, Del Campo JA, Maya-Miles D, Montero-Vallejo R, Cárdenas-García A, Pareja MJ, Gato-Zambrano S, et al: Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. Sci Rep. 12:34182022. View Article : Google Scholar : PubMed/NCBI

Wu B, Feng J, Guo J, Wang J, Xiu G and Xu J, Ning K, Ling B, Fu Q and Xu J: ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. Stem Cell Res Ther. 13:4942022. View Article : Google Scholar : PubMed/NCBI

Li L, Mao Y, Zhao L, Li L, Wu J, Zhao M, Du W, Yu L and Jiang P: p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis. Nature. 567:253–256. 2019. View Article : Google Scholar : PubMed/NCBI

Thomsen KL, Eriksen PL, Kerbert AJ, De Chiara F, Jalan R and Vilstrup H: Role of ammonia in NAFLD: An unusual suspect. JHEP Rep. 5:1007802023. View Article : Google Scholar : PubMed/NCBI

Zheng W, Guan F, Xu G, Yu Y, Xiao J and Huang X: FAT10 silencing prevents liver fibrosis through regulating SIRT1 expression in hepatic stellate cells. Int J Med Sci. 20:557–565. 2023. View Article : Google Scholar : PubMed/NCBI

He J, Deng C, Krall L and Shan Z: ScRNA-seq and ST-seq in liver research. Cell Regen. 12:112023. View Article : Google Scholar : PubMed/NCBI

Gilgenkrantz H, Mallat A, Moreau R and Lotersztajn S: Targeting cell-intrinsic metabolism for antifibrotic therapy. J Hepatol. 74:1442–1454. 2021. View Article : Google Scholar : PubMed/NCBI

Sun Y, Chen X, Chen L, Bao B, Li C and Zhou Y: MFAP2 promotes HSCs activation through FBN1/TGF-β/Smad3 pathway. J Cell Mol Med. 27:3235–3246. 2023. View Article : Google Scholar : PubMed/NCBI

Li HM, Zhang JY, Wang XQ, Ye LT, Ren B, Leng YH, Zhang JX, Yang Y, Jiang Q, Feng LL, et al: Therapeutic potential of PDA@CeO2 in suppressing hepatic stellate cell activation and preventing liver fibrosis. Int J Nanomedicine. 20:9073–9091. 2025. View Article : Google Scholar : PubMed/NCBI

Li C, Zhan Y, Zhang R, Tao Q, Lang Z and Zheng J: 20(S)-Protopanaxadiol suppresses hepatic stellate cell activation via WIF1 demethylation-mediated inactivation of the Wnt/β-catenin pathway. J Ginseng Res. 47:515–523. 2023. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Shang J, Yang Q, Dai Z, Liang Y, Lai C, Feng T, Zhong D, Zou H, Sun L, et al: Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism. J Nanobiotechnology. 21:292023. View Article : Google Scholar : PubMed/NCBI

Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, et al: GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 155:1463–1473.e6. 2018. View Article : Google Scholar : PubMed/NCBI

Bhattacharya D, Basta B, Mato JM, Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, et al: Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Rep. 3:1002372021. View Article : Google Scholar : PubMed/NCBI

Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, et al: Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 27:1825–1835. 2021. View Article : Google Scholar : PubMed/NCBI

Tacke F, Puengel T, Loomba R and Friedman SL: An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 79:552–566. 2023. View Article : Google Scholar : PubMed/NCBI

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, et al: Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 394:2012–2024. 2019. View Article : Google Scholar : PubMed/NCBI

Yabut JM and Drucker DJ: Glucagon-like Peptide-1 Receptor-based therapeutics for metabolic liver disease. Endocr Rev. 44:14–32. 2023. View Article : Google Scholar

Desjardins EM, Wu J, Lavoie DCT, Ahmadi E, Townsend LK, Morrow MR, Wang D, Tsakiridis EE, Batchuluun B, Fayyazi R, et al: Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. Cell Rep Med. 4:1011932023. View Article : Google Scholar : PubMed/NCBI

Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, et al: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One. 15:e2222592020. View Article : Google Scholar

Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, et al: Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 39:1468–1477. 2019. View Article : Google Scholar : PubMed/NCBI

Brauer NR, Kempen AL, Hernandez D and Sintim HO: Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors. Eur J Med Chem. 275:1165402024. View Article : Google Scholar : PubMed/NCBI

Pesce A, Ciurleo R, Bramanti A, Armeli Iapichino EC, Petralia MC, Magro GG, Fagone P, Bramanti P, Nicoletti F and Mangano K: Effects of combined admistration of imatinib and sorafenib in a murine model of liver fibrosis. Molecules. 25:43102020. View Article : Google Scholar : PubMed/NCBI

Hany NM, Eissa S, Basyouni M, Hasanin AH, Aboul-Ela YM, Elmagd NMA, Montasser IF, Ali MA, Skipp PJ and Matboli M: Modulation of hepatic stellate cells by Mutaflor((R)) probiotic in non-alcoholic fatty liver disease management. J Transl Med. 20:3422022. View Article : Google Scholar

Habash NW, Sehrawat TS, Shah VH and Cao S: Epigenetics of alcohol-related liver diseases. JHEP Rep. 4:1004662022. View Article : Google Scholar : PubMed/NCBI

Pan XY, You HM, Wang L, Bi YH, Yang Y, Meng HW, Meng XM, Ma TT, Huang C and Li J: Methylation of RCAN1.4 mediated by DNMT1 and DNMT3b enhances hepatic stellate cell activation and liver fibrogenesis through Calcineurin/NFAT3 signaling. Theranostics. 9:4308–4323. 2019. View Article : Google Scholar : PubMed/NCBI

Wang X, He Y, Mackowiak B and Gao B: MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 70:784–795. 2021. View Article : Google Scholar

Lucantoni F, Martinez-Cerezuela A, Gruevska A, Moragrega ÁB, Víctor VM, Esplugues JV, Blas-García A and Apostolova N: Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: Are we there yet? J Pathol. 254:216–228. 2021. View Article : Google Scholar : PubMed/NCBI

Le TV, Phan-Thi HT, Huynh-Thi MX, Dang TM, Holterman AXL, Grassi G, Nguyen-Luu TU and Truong NH: Autophagy inhibitor chloroquine downmodulates hepatic stellate cell activation and liver damage in bile-duct-ligated mice. Cells. 12:10252023. View Article : Google Scholar : PubMed/NCBI

Yu X, Elfimova N, Muller M, Bachurski D, Koitzsch U, Drebber U, Mahabir E, Hansen HP, Friedman SL, Klein S, et al: Autophagy-related activation of hepatic stellate cells reduces cellular miR-29a by promoting its vesicular secretion. Cell Mol Gastroenterol Hepatol. 13:1701–1716. 2022. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Yao Z, Zhao S, Shao J, Chen A, Zhang F and Zheng S: Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis. Cell Death Dis. 8:e28862017. View Article : Google Scholar : PubMed/NCBI

Bao YN, Yang Q, Shen XL, Yu WK, Zhou L, Zhu QR, Shan QY, Wang ZC and Cao G: Targeting tumor suppressor p53 for organ fibrosis therapy. Cell Death Dis. 15:3362024. View Article : Google Scholar : PubMed/NCBI

Yan M, Cui Y and Xiang Q: Metabolism of hepatic stellate cells in chronic liver diseases: Emerging molecular and therapeutic interventions. Theranostics. 15:1715–1740. 2025. View Article : Google Scholar : PubMed/NCBI

He S, Luo Y, Ma W, Wang X, Yan C, Hao W, Fang Y, Su H, Lai B, Liu J, et al: Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis. J Hepatol. 81:135–148. 2024. View Article : Google Scholar : PubMed/NCBI

Kisseleva T and Brenner D: Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 18:151–166. 2021. View Article : Google Scholar

Maretti-Mira AC, Salomon MP, Hsu AM, Dara L and Golden-Mason L: Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity. Front Immunol. 14:11370342023. View Article : Google Scholar : PubMed/NCBI

Xu F, Gao Y, Li T, Jiang T, Wu X, Yu Z, Zhang J, Hu Y and Cao J: Single-cell sequencing reveals the heterogeneity of hepatic natural killer cells and identifies the cytotoxic natural killer subset in schistosomiasis mice. Int J Mol Sci. 26:32112025. View Article : Google Scholar : PubMed/NCBI

Ma X, Qiu J, Zou S, Tan L and Miao T: The role of macrophages in liver fibrosis: Composition, heterogeneity, and therapeutic strategies. Front Immunol. 15:14942502024. View Article : Google Scholar : PubMed/NCBI

Wang WM, Xu XS and Miao CM: Kupffer cell-derived TNF-α triggers the apoptosis of hepatic stellate cells through TNF-R1/Caspase 8 due to ER stress. Biomed Res Int. 2020:80356712020. View Article : Google Scholar

Jia K, Ma Z, Zhang Y, Xie K, Li J, Wu J, Qu J, Li F and Li X: Picroside II promotes HSC apoptosis and inhibits the cholestatic liver fibrosis in Mdr2(-/-) mice by polarizing M1 macrophages and balancing immune responses. Chin J Nat Med. 22:582–598. 2024.PubMed/NCBI

Li Y, Zhang Y, Pan G, Xiang LX, Luo DC and Shao JZ: Occurrences and functions of Ly6C(hi) and Ly6C(lo) macrophages in health and disease. Front Immunol. 13:9016722022. View Article : Google Scholar : PubMed/NCBI

Zhou Z, Qi J, Zhao J, Lim CW, Kim JW and Kim B: Dual TBK1/IKKε inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice. J Cell Mol Med. 24:1383–1398. 2020. View Article : Google Scholar

Lai Q, Li W, Hu D, Huang Z, Wu M, Feng S and Wan Y: Hepatic stellate cell-targeted chemo-gene therapy for liver fibrosis using fluorinated peptide-lipid hybrid nanoparticles. J Control Release. 376:601–617. 2024. View Article : Google Scholar : PubMed/NCBI

Lee SW, Kim SM, Hur W, Kang BY, Lee HL, Nam H, Yoo SH, Sung PS, Kwon JH, Jang JW, et al: Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway. PLoS One. 16:e2610672021. View Article : Google Scholar

Fondevila MF, Novoa E, Gonzalez-Rellan MJ, Fernandez U, Heras V, Porteiro B, Parracho T, Dorta V, Riobello C, da Silva Lima N, et al: p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway. Cell Rep Med. 5:1014012024. View Article : Google Scholar : PubMed/NCBI

Trinh VQ, Lee TF, Lemoinne S, Ray KC, Ybanez MD, Tsuchida T, Carter JK, Agudo J, Brown BD, Akat KM, et al: Hepatic stellate cells maintain liver homeostasis through paracrine neurotrophin-3 signaling that induces hepatocyte proliferation. Sci Signal. 16:f66962023. View Article : Google Scholar

Yang F, Li H, Li Y, Hao Y, Wang C, Jia P, Chen X, Ma S and Xiao Z: Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. Int Immunopharmacol. 99:1080512021. View Article : Google Scholar : PubMed/NCBI

Vyas K and Patel MM: Insights on drug and gene delivery systems in liver fibrosis. Asian J Pharm Sci. 18:1007792023.PubMed/NCBI

Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, et al: BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 75:912–923. 2022. View Article : Google Scholar

Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N and Murakami Y: MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice. Mol Ther. 24:1848–1859. 2016. View Article : Google Scholar : PubMed/NCBI

Zhang C, Teng Y, Li F, Ho W, Bai X, Xu X and Zhang XQ: Nanoparticle-Mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells. ACS Nano. 17:14852–14870. 2023. View Article : Google Scholar : PubMed/NCBI

Weber F, Casalini T, Valentino G, Brülisauer L, Andreas N, Koeberle A, Kamradt T, Contini A and Luciani P: Targeting transdifferentiated hepatic stellate cells and monitoring the hepatic fibrogenic process by means of IGF2R-specific peptides designed in silico. J Mater Chem B. 9:2092–2106. 2021. View Article : Google Scholar : PubMed/NCBI

Puche JE, Lee YA, Jiao J, Aloman C, Fiel MI, Muñoz U, Kraus T, Lee T, Yee HF Jr and Friedman SL: A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice. Hepatology. 57:339–350. 2013. View Article : Google Scholar

Cortes E, Lachowski D, Rice A, Thorpe SD, Robinson B, Yeldag G, Lee DA, Ghemtio L, Rombouts K and Del Río Hernández AE: Tamoxifen mechanically deactivates hepatic stellate cells via the G protein-coupled estrogen receptor. Oncogene. 38:2910–2922. 2019. View Article : Google Scholar :

Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, et al: Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 155:1140–1153. 2018. View Article : Google Scholar : PubMed/NCBI

Masuda A, Nakamura T, Abe M, Iwamoto H, Sakaue T, Tanaka T, Suzuki H, Koga H and Torimura T: Promotion of liver regeneration and anti-fibrotic effects of the TGF-β receptor kinase inhibitor galunisertib in CCl4-treated mice. Int J Mol Med. 46:427–438. 2020. View Article : Google Scholar : PubMed/NCBI

Huang J, Huang H, Wang Y, Xu B, Lin M, Han S, Yuan Y, Wang Y and Shuai X: Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation. Biomaterials. 299:1221342023. View Article : Google Scholar : PubMed/NCBI

Ramani K, Mavila N, Abeynayake A, Tomasi ML, Wang J, Matsuda M and Seki E: Targeting A-kinase anchoring protein 12 phosphorylation in hepatic stellate cells regulates liver injury and fibrosis in mouse models. Elife. 11:e784302022. View Article : Google Scholar : PubMed/NCBI

Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K and Tsukamoto H: Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem. 279:11392–11401. 2004. View Article : Google Scholar : PubMed/NCBI

Nakano Y, Kamiya A, Sumiyoshi H, Tsuruya K, Kagawa T and Inagaki Y: A deactivation factor of fibrogenic hepatic stellate cells induces regression of liver fibrosis in mice. Hepatology. 71:1437–1452. 2020. View Article : Google Scholar

Luo J, Li L, Chang B, Zhu Z, Deng F, Hu M, Yu Y, Lu X, Chen Z, Zuo D and Zhou J: Mannan-binding lectin via interaction with cell surface calreticulin promotes senescence of activated hepatic stellate cells to limit liver fibrosis progression. Cell Mol Gastroenterol Hepatol. 14:75–99. 2022. View Article : Google Scholar : PubMed/NCBI

Guo Q, Chen M, Chen Q, Xiao G, Chen Z, Wang X and Huang Y: Silencing p53 inhibits interleukin 10-induced activated hepatic stellate cell senescence and fibrotic degradation in vivo. Exp Biol Med (Maywood). 246:447–458. 2021. View Article : Google Scholar

Huang YH, Chen MH, Guo QL, Chen ZX, Chen QD and Wang XZ: Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis. Cell Signal. 66:1094452020. View Article : Google Scholar

Barcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, et al: Dual targeting of histone methyltransferase G9a and DNA-Methyltransferase 1 for the treatment of experimental hepatocellular carcinoma. Hepatology. 69:587–603. 2019. View Article : Google Scholar

Barcena-Varela M, Paish H, Alvarez L, Uriarte I, Latasa MU, Santamaria E, Recalde M, Garate M, Claveria A, Colyn L, et al: Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. Gut. 70:388–400. 2021. View Article : Google Scholar

Lu P, Yan M, He L, Li J, Ji Y and Ji J: Crosstalk between epigenetic modulations in valproic acid deactivated hepatic stellate cells: An integrated protein and miRNA profiling study. Int J Biol Sci. 15:93–104. 2019. View Article : Google Scholar : PubMed/NCBI

Yang J, Lu Y, Yang P, Chen Q, Wang Y, Ding Q, Xu T, Li X, Li C, Huang C, et al: MicroRNA-145 induces the senescence of activated hepatic stellate cells through the activation of p53 pathway by ZEB2. J Cell Physiol. 234:7587–7599. 2019. View Article : Google Scholar

Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay HC, Yang D, Reetz J, Brandes S, Dai Z, Pützer BM, et al: Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis. Cell Stem Cell. 18:797–808. 2016. View Article : Google Scholar : PubMed/NCBI

Rezvani M, Espanol-Suner R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, et al: In vivo hepatic reprogramming of myofibroblasts with AAV Vectors as a therapeutic strategy for liver fibrosis. Cell Stem Cell. 18:809–816. 2016. View Article : Google Scholar : PubMed/NCBI

Heslop JA and Duncan SA: FoxA factors: The chromatin key and doorstop essential for liver development and function. Genes Dev. 34:1003–1004. 2020. View Article : Google Scholar : PubMed/NCBI

Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM and Duncan SA: Hepatocyte nuclear factor 4alpha orchestrates expression of cell adhesion proteins during the epithelial transformation of the developing liver. Proc Natl Acad Sci USA. 103:8419–8424. 2006. View Article : Google Scholar : PubMed/NCBI

Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, Thoen LF, Hoorens A, Reynaert H, Halder G and van Grunsven LA: The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol. 63:679–688. 2015. View Article : Google Scholar : PubMed/NCBI

Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, Dalton GD, Thelen E, Rizi BS, Jung Y and Diehl AM: Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. 154:1465–1479.e13. 2018. View Article : Google Scholar : PubMed/NCBI